Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI South East AsiaCPhI South East Asia
Not Confirmed
Not Confirmed
16-18 July, 2025
Specialty & Agro Chemi...Specialty & Agro Chemical
Not Confirmed
Not Confirmed
29 June-01 July, 2025
Discovery EuropeDiscovery Europe
Not Confirmed
Not Confirmed
01-02 July, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI South East AsiaCPhI South East Asia
Industry Trade Show
Not Confirmed
16-18 July, 2025
Specialty & Agro Chemi...Specialty & Agro Chemical
Industry Trade Show
Not Confirmed
29 June-01 July, 2025
Discovery EuropeDiscovery Europe
Industry Trade Show
Not Confirmed
01-02 July, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/j-j-s-intra-cellular-buyout-bms-oncology-gambit-sanofi-s-blueprint-acquisition-drive-mega-deals-in-h1-2025
16 Apr 2025
// FDA
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-16-2025-39741.pdf
10 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/b-braun-medical-inc-announces-us-fda-approval-of-piperacillin-and-tazobactam-for-injection-and-sodium-chloride-injection-in-the-duplex-drug-delivery-system-302423758.html
24 Mar 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/b-braun-launches-ready-to-activate-cefazolin-3-gram-pre-mix-in-duplex-containers-302409337.html
16 Aug 2024
// FIERCE PHARMA
https://www.fiercepharma.com/pharma/b-braun-baxter-launch-separate-recalls-over-particulate-concerns-and-excess-endotoxin-levels
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/b-braun-issues-voluntary-nationwide-recall-09-sodium-chloride-injection-usp-1000-ml-e3-containers
12 Jun 2024
// PHARMABIZ
Details:
Piperacillin, a penicillin-class antibacterial, and Tazobactam, a beta-lactamase inhibitor, in the DUPLEX Drug Delivery System and Sodium Chloride, indicated for Intra-abdominal infections.
Lead Product(s): Piperacillin Sodium,Tazobactam Sodium
Therapeutic Area: Infections and Infectious Diseases Brand Name: Piperacillin and Tazobactam for Injection
Study Phase: Approved FDFProduct Type: Antibiotic
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 09, 2025
Lead Product(s) : Piperacillin Sodium,Tazobactam Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
B. Braun Gains FDA Approval for DUPLEX Delivery of Piperacillin Combo
Details : Piperacillin, a penicillin-class antibacterial, and Tazobactam, a beta-lactamase inhibitor, in the DUPLEX Drug Delivery System and Sodium Chloride, indicated for Intra-abdominal infections.
Product Name : Piperacillin and Tazobactam for Injection
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 09, 2025
Details:
Cefazolin sodium is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. It is indicated for several infections, like respiratory, urinary infections in adult and pediatric.
Lead Product(s): Cefazolin Sodium,Dextrose
Therapeutic Area: Infections and Infectious Diseases Brand Name: Cefazolin Sodium Injection
Study Phase: Approved FDFProduct Type: Antibiotic
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 24, 2025
Lead Product(s) : Cefazolin Sodium,Dextrose
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
B. Braun Launches Ready-to-Activate Cefazolin 3 Gram Pre-Mix in DUPLEX® Containers
Details : Cefazolin sodium is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. It is indicated for several infections, like respiratory, urinary infections in adult and pediatric.
Product Name : Cefazolin Sodium Injection
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 24, 2025
Details:
Levetiracetam is indicated for adjunctive therapy in the treatment of Partial onset seizures in patients one month of age and older with epilepsy.
Lead Product(s): Levetiracetam
Therapeutic Area: Neurology Brand Name: Levetiracetam-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 28, 2024
Lead Product(s) : Levetiracetam
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
B. Braun Launches Levetiracetam in Sodium Chloride Injection Portfolio
Details : Levetiracetam is indicated for adjunctive therapy in the treatment of Partial onset seizures in patients one month of age and older with epilepsy.
Product Name : Levetiracetam-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 28, 2024
Details:
The acquisition includes a qualified cell bank, which is essential for the GMP-compliant manufacturing of Healiva’s first cell therapy product, EpiDex®: an autologous epidermis derived from the patient’s own hair cells.
Lead Product(s): Tissue-engineered Autologous Outer Root Sheath Keratinocyte
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Epidex
Study Phase: Approved FDFProduct Type: Cell and Gene therapy
Sponsor: Healiva
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 21, 2022
Lead Product(s) : Tissue-engineered Autologous Outer Root Sheath Keratinocyte
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Healiva
Deal Size : Undisclosed
Deal Type : Acquisition
Healiva® Acquires Critical Cell Therapy Manufacturing Assets From B. Braun
Details : The acquisition includes a qualified cell bank, which is essential for the GMP-compliant manufacturing of Healiva’s first cell therapy product, EpiDex®: an autologous epidermis derived from the patient’s own hair cells.
Product Name : Epidex
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 21, 2022
Excipients
Inspections and registrations
District Decision : Voluntary Action Indicated
Inspection End Date : 2015-06-18
City : Melsungen
State :
Country/Area : DE
Zip :
District : ORA
Center : CDRH
Project Area : Postmarket Assurance: Devices
District Decision : Voluntary Action Indicated
Inspection End Date : 2015-06-18
District Decision : Voluntary Action Indicated
Inspection End Date : 2015-06-18
City : Melsungen
State :
Country/Area : DE
Zip :
District : ORA
Center : CDRH
Project Area : Compliance: Devices
District Decision : Voluntary Action Indicated
Inspection End Date : 2015-06-18
District Decision : No Action Indicated
Inspection End Date : 2015-02-19
City : Melsungen
State :
Country/Area : DE
Zip :
District : ORA
Center : CDRH
Project Area : Postmarket Assurance: Devices
District Decision : No Action Indicated
Inspection End Date : 2015-02-19
District Decision : Voluntary Action Indicated
Inspection End Date : 2015-02-19
City : Melsungen
State :
Country/Area : DE
Zip :
District : ORA
Center : CDRH
Project Area : Compliance: Devices
District Decision : Voluntary Action Indicated
Inspection End Date : 2015-02-19
District Decision : No Action Indicated
Inspection End Date : 2014-11-13
City : Crissier
State :
Country/Area : CH
Zip :
District : ORA
Center : CDER
Project Area : Drug Quality Assurance
District Decision : No Action Indicated
Inspection End Date : 2014-11-13
District Decision : No Action Indicated
Inspection End Date : 2014-06-03
City : Sempach
State :
Country/Area : CH
Zip :
District : ORA
Center : CDRH
Project Area : Compliance: Devices
District Decision : No Action Indicated
Inspection End Date : 2014-06-03
District Decision : No Action Indicated
Inspection End Date : 2014-05-20
City : Melsungen
State :
Country/Area : DE
Zip :
District : ORA
Center : CDER
Project Area : Drug Quality Assurance
District Decision : No Action Indicated
Inspection End Date : 2014-05-20
District Decision : Voluntary Action Indicated
Inspection End Date : 2014-04-10
City : Tochigitochigi
State :
Country/Area : JP
Zip :
District : ORA
Center : CDRH
Project Area : Compliance: Devices
District Decision : Voluntary Action Indicated
Inspection End Date : 2014-04-10
District Decision : Voluntary Action Indicated
Inspection End Date : 2014-03-20
City : Rubi
State :
Country/Area : ES
Zip :
District : ORA
Center : CDRH
Project Area : Compliance: Devices
District Decision : Voluntary Action Indicated
Inspection End Date : 2014-03-20
District Decision : Voluntary Action Indicated
Inspection End Date : 2014-02-13
City : Irvine
State : CA
Country/Area : US
Zip : 92614
District : LOS
Center : CDER
Project Area : Drug Quality Assurance
District Decision : Voluntary Action Indicated
Inspection End Date : 2014-02-13
ABOUT THIS PAGE
B. Braun Medical is a supplier offers 7 products (APIs, Excipients or Intermediates).
Find a price of Hydroxyethyl Starch bulk with CEP offered by B. Braun Medical
Find a price of Amino Acids, Branched-Chain bulk offered by B. Braun Medical
Find a price of Cornstarch bulk offered by B. Braun Medical
Find a price of OMEGAFLEX SPECIAL (THREE CHAMBER BAG FOR INFUSION CONTAINING: AMINO ACIDS, GLUCOSE, AND LIPID EMULSION) bulk offered by B. Braun Medical
Find a price of MOIST HEAT STERILIZATION PARAMETRIC RELEASE PROGRAM (CA AND GA PLANTS) bulk offered by B. Braun Medical
Find a price of PERSONNEL bulk offered by B. Braun Medical
Find a price of FACILITIES & GENERAL OPERATING PROCEDS AT IRVINE, CALIF bulk offered by B. Braun Medical